A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG)
The purpose of this study is to determine if eculizumab is safe and effective for the treatment of patients with refractory gMG.
Location: CPMC (San Francisco)
Please contact ClinicalResearch@sutterhealth.org about Study Refractory MG.
View study details on ClinicalTrials.gov
Subjects with generalized myasthenia gravis (gMG) who have needed at least two immunosuppressive drugs, or one immunosuppressive drug and regular plasma exchange or IVIG to control symptoms.
Contact site for start date.
June 01, 2018